TLR stimulation of prostate tumor cells induces chemokine-mediated recruitment of specific immune cell types

Journal of Immunology

Volumn 184, Issue 12, 2010, Pages 6658-6669

  Galli, Roberta ^a   Starace, Donatella ^a   Busà, Roberta ^b,c   Angelini, Daniela F ^c   Paone, Alessio ^a   De Cesaris, Paola ^d   Filippini, Antonio ^a   Sette, Claudio ^b,c   Battistini, Luca ^c   Ziparo, Elio ^a   Riccioli, Anna ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^d UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; FLAGELLIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 5; MESSENGER RNA; TLR3 PROTEIN, HUMAN; TLR5 PROTEIN, HUMAN;

ADAPTIVE IMMUNITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; INFLAMMATION; INNATE IMMUNITY; LEUKOCYTE COUNT; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROSTATE TUMOR; UPREGULATION; DNA MICROARRAY; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION REGULATION; IMMUNOLOGY; MALE; METABOLISM; NEUTROPHIL CHEMOTAXIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; CHEMOKINES; CHEMOTAXIS, LEUKOCYTE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMANS; MALE; NF-KAPPA B; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 3; TOLL-LIKE RECEPTOR 5;

EID: 77953634689     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0902401     Document Type: Article

References (63)

1. Takeda, K., T. Kaisho, and S. Akira. 2003. Toll-like receptors. Annu. Rev. Immunol. 21: 335-376.
2. Akira, S., and K. Takeda. 2004. Toll-like receptor signalling. Nat. Rev. Immunol. 4: 499-511.
3. Pasare, C., and R. Medzhitov. 2003. Toll pathway-dependent blockade of CD4+ CD25+ T cell-mediated suppression by dendritic cells. Science 299: 1033-1036. (Pubitemid 36222922)
4. Starace, D., R. Galli, A. Paone, P. De Cesaris, A. Filippini, E. Ziparo, and A. Riccioli. 2008. Toll-like receptor 3 activation induces antiviral immune responses in mouse sertoli cells. Biol. Reprod. 79: 766-775.
5. Picker, L. J., and E. C. Butcher. 1992. Physiological and molecular mechanisms of lymphocyte homing. Annu. Rev. Immunol. 10: 561-591.
6. Rakoff-Nahoum, S., and R. Medzhitov. 2009. Toll-like receptors and cancer. Nat. Rev. Cancer 9: 57-63.
7. Krieg, A. M. 2007. Development of TLR9 agonists for cancer therapy. J. Clin. Invest. 117: 1184-1194.
8. Paone, A., D. Starace, R. Galli, F. Padula, P. De Cesaris, A. Filippini, E. Ziparo, and A. Riccioli. 2008. Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alpha-dependent mechanism. Carcinogenesis 29: 1334-1342.
9. Salaun, B., I. Coste, M. C. Rissoan, S. J. Lebecque, and T. Renno. 2006. TLR3 can directly trigger apoptosis in human cancer cells. J. Immunol. 176: 4894-4901.
10. Nogueras, S., A. Merino, R. Ojeda, J. Carracedo, M. Rodriguez, A. Martin-Malo, R. Ramírez, and P. Aljama. 2008. Coupling of endothelial injury and repair: an analysis using an in vivo experimental model. Am. J. Physiol. Heart Circ. Physiol. 294: H708-H713.
11. McSorley, S. J., B. D. Ehst, Y. Yu, and A. T. Gewirtz. 2002. Bacterial flagellin is an effective adjuvant for CD4+ T cells in vivo. J. Immunol. 169: 3914-3919.
12. Jego, G., R. Bataille, A. Geffroy-Luseau, G. Descamps, and C. Pellat-Deceunynck. 2006. Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia 20: 1130-1137. (Pubitemid 43797308)
13. Mantovani, A., P. Allavena, A. Sica, and F. Balkwill. 2008. Cancer-related inflammation. Nature 454: 436-444.
14. Ben-Baruch, A. 2006. The multifaceted roles of chemokines in malignancy. Cancer Metastasis Rev. 25: 357-371.
15. Allavena, P., A. Sica, C. Garlanda, and A. Mantovani. 2008. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol. Rev. 222: 155-161.
16. Malmberg, K. J., Y. T. Bryceson, M. Carlsten, S. Andersson, A. Björklund, N. K. Björkström, B. C. Baumann, C. Fauriat, E. Alici, M. S. Dilber, and H. G. Ljunggren. 2008. NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy. Cancer Immunol. Immunother. 57: 1541-1552.
17. De Marzo, A. M., E. A. Platz, S. Sutcliffe, J. Xu, H. Grönberg, C. G. Drake, Y. Nakai, W. B. Isaacs, and W. G. Nelson. 2007. Inflammation in prostate carcinogenesis. Nat. Rev. Cancer 7: 256-269.
18. Cohen, R. J., B. A. Shannon, J. E. McNeal, T. Shannon, and K. L. Garrett. 2005. Propionibacterium acnes associated with inflammation in radical prostatectomy specimens: a possible link to cancer evolution? J. Urol. 173: 1969-1974.
19. Zambrano, A., M. Kalantari, A. Simoneau, J. L. Jensen, and L. P. Villarreal. 2002. Detection of human polyomaviruses and papillomaviruses in prostatic tissue reveals the prostate as a habitat for multiple viral infections. Prostate 53: 263-276.
20. Riley, D. E., R. E. Berger, D. C. Miner, and J. N. Krieger. 1998. Diverse and related 16S rRNA-encoding DNA sequences in prostate tissues of men with chronic prostatitis. J. Clin. Microbiol. 36: 1646-1652.
21. Urisman, A., R. J. Molinaro, N. Fischer, S. J. Plummer, G. Casey, E. A. Klein, K. Malathi, C. Magi-Galluzzi, R. R. Tubbs, D. Ganem, et al. 2006. Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog. 2: e25.
22. Pulukuri, S. M., C. S. Gondi, S. S. Lakka, A. Jutla, N. Estes, M. Gujrati, and J. S. Rao. 2005. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J. Biol. Chem. 280: 36529-36540.
23. Armstrong, L., A. R. Medford, K. M. Uppington, J. Robertson, I. R. Witherden, T. D. Tetley, and A. B. Millar. 2004. Expression of functional toll-like receptor-2 and -4 on alveolar epithelial cells. Am. J. Respir. Cell Mol. Biol. 31: 241-245.
24. Hasan, N., N. Yusuf, Z. Toossi, and N. Islam. 2006. Suppression of Mycobacterium tuberculosis induced reactive oxygen species (ROS) and TNF-alpha mRNA expression in human monocytes by allicin. FEBS Lett. 580: 2517-2522.
25. Kang, S. S., S. S. Woo, J. Im, J. S. Yang, C. H. Yun, H. R. Ju, C. G. Son, E. Y. Moon, and S. H. Han. 2007. Human placenta promotes IL-8 expression through activation of JNK/SAPK and transcription factors NF-kappaB and AP-1 in PMA-differentiated THP-1 cells. Int. Immunopharmacol. 7: 1488-1495.
26. Keller, C., P. Keller, S. Marshal, and B. K. Pedersen. 2003. IL-6 gene expression in human adipose tissue in response to exercise - effect of carbohydrate ingestion. J. Physiol. 550: 927-931.
27. Pisegna, S., G. Pirozzi, M. Piccoli, L. Frati, A. Santoni, and G. Palmieri. 2004. p38 MAPK activation controls the TLR3-mediated up-regulation of cytotoxicity and cytokine production in human NK cells. Blood 104: 4157-4164. (Pubitemid 39620169)
28. Zhang, Z., J. P. Louboutin, D. J. Weiner, J. B. Goldberg, and J. M. Wilson. 2005. Human airway epithelial cells sense Pseudomonas aeruginosa infection via recognition of flagellin by Toll-like receptor 5. Infect. Immun. 73: 7151-7160.
29. Björkström, N. K., V. D. Gonzalez, K. J. Malmberg, K. Falconer, A. Alaeus, G. Nowak, C. Jorns, B. G. Ericzon, O. Weiland, J. K. Sandberg, and H. G. Ljunggren. 2008. Elevated numbers of Fc gamma RIIIA+ (CD16+) effector CD8 T cells with NK cell-like function in chronic hepatitis C virus infection. J. Immunol. 181: 4219-4228.
30. Kawai, T., and S. Akira. 2007. Signaling to NF-kappaB by Toll-like receptors. Trends Mol. Med. 13: 460-469.
31. Baeuerle, P. A., and D. Baltimore. 1988. I kappa B: a specific inhibitor of the NF-kappa B transcription factor. Science 242: 540-546. (Pubitemid 18263193)
32. Andrejeva, J., K. S. Childs, D. F. Young, T. S. Carlos, N. Stock, S. Goodbourn, and R. E. Randall. 2004. The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter. Proc. Natl. Acad. Sci. USA 101: 17264-17269.
33. Yoneyama, M., M. Kikuchi, T. Natsukawa, N. Shinobu, T. Imaizumi, M. Miyagishi, K. Taira, S. Akira, and T. Fujita. 2004. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 5: 730-737.
34. Riccioli, A., D. Starace, R. Galli, A. Fuso, S. Scarpa, F. Palombi, P. De Cesaris, E. Ziparo, and A. Filippini. 2006. Sertoli cells initiate testicular innate immune responses through TLR activation. J. Immunol. 177: 7122-7130. (Pubitemid 44715080)
35. Zheng, J., J. Meng, S. Zhao, R. Singh, and W. Song. 2008. Campylobacter-induced interleukin-8 secretion in polarized human intestinal epithelial cells requires Campylobacter-secreted cytolethal distending toxin- and Toll-like receptor-mediated activation of NF-kappaB. Infect. Immun. 76: 4498-4508.
36. Beider, K., M. Abraham, M. Begin, H. Wald, I. D. Weiss, O. Wald, E. Pikarsky, R. Abramovitch, E. Zeira, E. Galun, et al. 2009. Interaction between CXCR4 and CCL20 pathways regulates tumor growth. PLoS ONE 4: e5125.
37. Vandercappellen, J., J. Van Damme, and S. Struyf. 2008. The role of CXC chemokines and their receptors in cancer. Cancer Lett. 267: 226-244.
38. Waugh, D. J., and C. Wilson. 2008. The interleukin-8 pathway in cancer. Clin. Cancer Res. 14: 6735-6741.
39. Guntermann, C., B. J. Murphy, R. Zheng, A. Qureshi, P. A. Eagles, and K. E. Nye. 1999. Human immunodeficiency virus-1 infection requires pertussis toxin sensitive G-protein-coupled signalling and mediates cAMP downregulation. Biochem. Biophys. Res. Commun. 256: 429-435.
40. Kabelitz, D. 2007. Expression and function of Toll-like receptors in T lymphocytes. Curr. Opin. Immunol. 19: 39-45.
41. Sivori, S., M. Falco, M. Della Chiesa, S. Carlomagno, M. Vitale, L. Moretta, and A. Moretta. 2004. CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proc. Natl. Acad. Sci. USA 101: 10116-10121.
42. Yang, J., K. I. Amiri, J. R. Burke, J. A. Schmid, and A. Richmond. 2006. BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways. Clin. Cancer Res. 12: 950-960.
43. El-Omar, E. M., M. T. Ng, and G. L. Hold. 2008. Polymorphisms in Toll-like receptor genes and risk of cancer. Oncogene 27: 244-252.
44. Takeyama, K., H. Mitsuzawa, T. Shimizu, M. Konishi, C. Nishitani, H. Sano, Y. Kunishima, M. Matsukawa, S. Takahashi, K. Shibata, et al. 2006. Prostate cell lines secrete IL-8 in response to Mycoplasma hominis through Toll-like receptor 2-mediated mechanism. Prostate 66: 386-391. (Pubitemid 43346949)
45. Droemann, D., D. Albrecht, J. Gerdes, A. J. Ulmer, D. Branscheid, E. Vollmer, K. Dalhoff, P. Zabel, and T. Goldmann. 2005. Human lung cancer cells express functionally active Toll-like receptor 9. Respir. Res. 6: 1.
46. Schmausser, B., M. Andrulis, S. Endrich, H. K. Müller-Hermelink, and M. Eck. 2005. Toll-like receptors TLR4, TLR5 and TLR9 on gastric carcinoma cells: an implication for interaction with Helicobacter pylori. Int. J. Med. Microbiol. 295: 179-185.
47. Xie, W., Y. Wang, Y. Huang, H. Yang, J. Wang, and Z. Hu. 2009. Toll-like receptor 2 mediates invasion via activating NF-kappaB in MDA-MB-231 breast cancer cells. Biochem. Biophys. Res. Commun. 379: 1027-1032.
48. Colotta, F., P. Allavena, A. Sica, C. Garlanda, and A. Mantovani. 2009. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30: 1073-1081.
49. Baud, V., and M. Karin. 2009. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat. Rev. Drug Discov. 8: 33-40.
50. Rhee, S. H., E. Im, and C. Pothoulakis. 2008. Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer. Gastroenterology 135: 518-528.
51. Sfondrini, L., A. Rossini, D. Besusso, A. Merlo, E. Tagliabue, S. Mènard, and A. Balsari. 2006. Antitumor activity of the TLR-5 ligand flagellin in mouse models of cancer. J. Immunol. 176: 6624-6630. (Pubitemid 43787845)
52. Challacombe, J. M., A. Suhrbier, P. G. Parsons, B. Jones, P. Hampson, D. Kavanagh, G. E. Rainger, M. Morris, J. M. Lord, T. T. Le, et al. 2006. Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. J. Immunol. 177: 8123-8132.
53. Tosch, C., M. Geist, C. Ledoux, C. Ziller-Remi, S. Paul, P. Erbs, N. Corvaia, P. Von Hoegen, J. M. Balloul, and H. Haegel. 2009. Adenovirus-mediated gene transfer of pathogen-associated molecular patterns for cancer immunotherapy. Cancer Gene Ther. 16: 310-319.
54. Kondo, T., and M. Takiguchi. 2009. Human memory CCR4+CD8+ T cell subset has the ability to produce multiple cytokines. Int. Immunol. 21: 523-532.
55. Berahovich, R. D., N. L. Lai, Z. Wei, L. L. Lanier, and T. J. Schall. 2006. Evidence for NK cell subsets based on chemokine receptor expression. J. Immunol. 177: 7833-7840.
56. Conforti, R., Y. Ma, Y. Morel, C. Paturel, M. Terme, S. Viaud, B. Ryffel, M. Ferrantini, R. Uppaluri, R. Schreiber, et al. 2010. Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. Cancer Res. 70: 490-500.
57. Coca, S., J. Perez-Piqueras, D. Martinez, A. Colmenarejo, M. A. Saez, C. Vallejo, J. A. Martos, and M. Moreno. 1997. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 79: 2320-2328. (Pubitemid 27251014)
58. Ishigami, S., S. Natsugoe, K. Tokuda, A. Nakajo, X. Che, H. Iwashige, K. Aridome, S. Hokita, and T. Aikou. 2000. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 88: 577-583. (Pubitemid 30056932)
59. Jamieson, A. M., A. Diefenbach, C. W. McMahon, N. Xiong, J. R. Carlyle, and D. H. Raulet. 2002. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 17: 19-29.
60. Raja Gabaglia, C., Y. Diaz de Durana, F. L. Graham, J. Gauldie, E. E. Sercarz, and T. A. Braciak. 2007. Attenuation of the glucocorticoid response during Ad5IL-12 adenovirus vector treatment enhances natural killer cell-mediated killing of MHC class I-negative LNCaP prostate tumors. Cancer Res. 67: 2290-2297.
61. Singh, S. V., R. Warin, D. Xiao, A. A. Powolny, S. D. Stan, J. A. Arlotti, Y. Zeng, E. R. Hahm, S. W. Marynowski, A. Bommareddy, et al. 2009. Sulforaphane inhibits prostate carcinogenesis and pulmonary metastasis in TRAMP mice in association with increased cytotoxicity of natural killer cells. Cancer Res. 69: 2117-2125.
62. Zitvogel, L., L. Apetoh, F. Ghiringhelli, F. André, A. Tesniere, and G. Kroemer. 2008. The anticancer immune response: indispensable for therapeutic success? J. Clin. Invest. 118: 1991-2001.
63. Adams, M., H. Navabi, D. Croston, S. Coleman, Z. Tabi, A. Clayton, B. Jasani, and M. D. Mason. 2005. The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer. Vaccine 23: 2374-2378.